Recursion Pharmaceuticals (RXRX) ended the recent trading session at $4.65, demonstrating a -4.12% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.26%. Elsewhere, the Dow saw an upswing of 0.6%, while the tech-heavy Nasdaq appreciated by 0.25%.
Shares of the biotechnology company witnessed a gain of 3.63% over the previous month, beating the performance of the Medical sector with its gain of 0.92%, and the S&P 500's gain of 1.57%.
The upcoming earnings release of Recursion Pharmaceuticals will be of great interest to investors. The company is predicted to post an EPS of -$0.28, indicating a 47.17% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $25.5 million, showing a 460.44% escalation compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.59 per share and revenue of $64.62 million, indicating changes of +5.92% and 0%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Recursion Pharmaceuticals. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 16.69% upward. Right now, Recursion Pharmaceuticals possesses a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 100, this industry ranks in the top 41% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Recursion Pharmaceuticals, Inc. (RXRX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
